2025年6月30日,艾伯维与生物技术公司Capstan Therapeutics, Inc.(“Capstan”)共同宣布达成最终收购协议。艾伯维将收购Capstan及其在研产品CPTX2309。CPTX2309是一种潜在“首创”(first-in-class)的体内tLNP抗CD19 CAR-T疗法候选药物,目前处于Ⅰ期临床阶段,用于治疗B细胞介导的自身免疫性疾病。此外,艾伯维还将获得...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.